Discontinued — last reported Q2 '24
Neuroscience — Impairment of indefinite-lived intangible assets
Over 3 years (FY 2021 to FY 2024), Neuroscience — Impairment of indefinite-lived intangible assets shows a downward trend with a -100.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase signals a decline in the expected future economic benefits of the segment's intangible assets, potentially due to competitive pressures, regulatory changes, or brand erosion. A consistent zero value suggests that the segment's intangible assets are maintaining or exceeding their carrying value.
Detailed definition
This metric measures the reduction in the carrying value of intangible assets with indefinite useful lives, such as acqu...
Peer comparison
Comparable to 'Impairment of intangible assets' or 'Write-down of indefinite-lived intangibles' reported by peers in the life sciences and medical technology sectors.
mdt_segment_neuroscience_impairment_of_indefinite_lived_intangible_assetsHistorical Data
| FY'21 | FY'22 | FY'23 | FY'24 | |
|---|---|---|---|---|
| Value | $45.00M | $0.00 | $0.00 | $0.00 |
| YoY Change | — | -100.0% | — | — |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Medtronic's neuroscience — impairment of indefinite-lived intangible assets?
- Medtronic (MDT) reported neuroscience — impairment of indefinite-lived intangible assets of $0.00 in Q1 2024.
- What is the long-term trend for Medtronic's neuroscience — impairment of indefinite-lived intangible assets?
- Over 3 years (2021 to 2024), Medtronic's neuroscience — impairment of indefinite-lived intangible assets has grown at a -100.0% compound annual growth rate (CAGR), from $45.00M to $0.00.
- What does neuroscience — impairment of indefinite-lived intangible assets mean?
- A non-cash charge taken when the value of indefinite-lived intangible assets, like brand names, is determined to have declined.